FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367018699> ?p ?o ?g. }

• W4367018699 abstract "Introduction Recent randomized controlled trials (RCT) failed to demonstrate non‐inferiority of skipping IV tPA in patients with planned endovascular therapy (EVT). None of these studies included patients from the US due to regulatory challenges. Given practice patterns vary relative to Asia and Europe, we sought to address this topic using a validated alternative to RCTs, fuzzy regression discontinuity design (RDD). Methods From our prospectively maintained multi‐center registry we identified patients with LVO AIS treated with EVT with and without IV tPA treatment from 1/2018 ‐ 9/2021. We used the time cutoff for IV tPA as our discontinuity and assumed subjects on either side of the cutoff have markedly different probabilities of receiving the treatment but are similar in other relevant characteristics. The primary outcome was good functional outcome defined as 90‐day mRS 0–2 and it was compared between these two populations immediately adjacent to the cutoff using local linear regressions. Results Among 694 patients with LVO AIS who received EVT, median age was 69 [IQR 59‐79], 50%, were female, 44% White, 24% Black, and 14% Hispanic. 51% received IV tPA, with median onset to treatment time of 109 min [IQR 79‐160]. We observed a sharp drop (47%) in the probability of tPA around the cutoff time of 4 hours (allowing 30 minutes for in‐hospital evaluation), while there were no significant differences in other relevant features at the cutoff, validating the underlying RDD assumptions (Figure A). Overall, 33% of patients achieved good functional outcomes and there were no significant differences around the cutoff time (Figure B). In fuzzy RDD, there was no evidence of an association of receiving tPA with good functional outcome with regression discontinuity of only 1.0% (p = 0.98)There were no significant differences in rates of hemorrhage in patients treated with or without IV tPA (22% vs 21%, p = 0.68). Conclusions Our study provides the highest quality US‐based evidence supporting the findings of the outside US trials, demonstrating no benefit of skipping IV tPA in patients with planned EVT." @default.
• W4367018699 created "2023-04-27" @default.
• W4367018699 creator A5000212230 @default.
• W4367018699 creator A5011108867 @default.
• W4367018699 creator A5024796482 @default.
• W4367018699 creator A5031684099 @default.
• W4367018699 creator A5056911306 @default.
• W4367018699 creator A5081219415 @default.
• W4367018699 creator A5083118897 @default.
• W4367018699 date "2023-03-01" @default.
• W4367018699 modified "2023-10-07" @default.
• W4367018699 title "Abstract Number ‐ 16: Thrombectomy alone versus Bridging intravenous alteplase in the US population: a pseudo‐randomized controlled trial" @default.
• W4367018699 doi "https://doi.org/10.1161/svin.03.suppl_1.016" @default.
• W4367018699 hasPublicationYear "2023" @default.
• W4367018699 type Work @default.
• W4367018699 citedByCount "0" @default.
• W4367018699 crossrefType "journal-article" @default.
• W4367018699 hasAuthorship W4367018699A5000212230 @default.
• W4367018699 hasAuthorship W4367018699A5011108867 @default.
• W4367018699 hasAuthorship W4367018699A5024796482 @default.
• W4367018699 hasAuthorship W4367018699A5031684099 @default.
• W4367018699 hasAuthorship W4367018699A5056911306 @default.
• W4367018699 hasAuthorship W4367018699A5081219415 @default.
• W4367018699 hasAuthorship W4367018699A5083118897 @default.
• W4367018699 hasBestOaLocation W43670186991 @default.
• W4367018699 hasConcept C121332964 @default.
• W4367018699 hasConcept C126322002 @default.
• W4367018699 hasConcept C141071460 @default.
• W4367018699 hasConcept C168563851 @default.
• W4367018699 hasConcept C2778217198 @default.
• W4367018699 hasConcept C2908647359 @default.
• W4367018699 hasConcept C62520636 @default.
• W4367018699 hasConcept C71924100 @default.
• W4367018699 hasConcept C99454951 @default.
• W4367018699 hasConceptScore W4367018699C121332964 @default.
• W4367018699 hasConceptScore W4367018699C126322002 @default.
• W4367018699 hasConceptScore W4367018699C141071460 @default.
• W4367018699 hasConceptScore W4367018699C168563851 @default.
• W4367018699 hasConceptScore W4367018699C2778217198 @default.
• W4367018699 hasConceptScore W4367018699C2908647359 @default.
• W4367018699 hasConceptScore W4367018699C62520636 @default.
• W4367018699 hasConceptScore W4367018699C71924100 @default.
• W4367018699 hasConceptScore W4367018699C99454951 @default.
• W4367018699 hasIssue "S1" @default.
• W4367018699 hasLocation W43670186991 @default.
• W4367018699 hasOpenAccess W4367018699 @default.
• W4367018699 hasPrimaryLocation W43670186991 @default.
• W4367018699 hasRelatedWork W2002120878 @default.
• W4367018699 hasRelatedWork W2003938723 @default.
• W4367018699 hasRelatedWork W2047967234 @default.
• W4367018699 hasRelatedWork W2118496982 @default.
• W4367018699 hasRelatedWork W2364998975 @default.
• W4367018699 hasRelatedWork W2369162477 @default.
• W4367018699 hasRelatedWork W2439875401 @default.
• W4367018699 hasRelatedWork W4238867864 @default.
• W4367018699 hasRelatedWork W2519357708 @default.
• W4367018699 hasRelatedWork W2525756941 @default.
• W4367018699 hasVolume "3" @default.
• W4367018699 isParatext "false" @default.
• W4367018699 isRetracted "false" @default.
• W4367018699 workType "article" @default.